Chugai Pharmaceutical Co., Ltd.

Tokyo Stock Exchange:4519.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 82.26 B

Share Price

USD 50.10

Avg Daily Volume

2,589,249

Change (1 day)

0.95%

Change (1 year)

54.89%

Change (YTD)

12.35%

Chugai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2024: USD 2.85 B

Chugai Pharmaceutical Co., Ltd. Operating Cash Flow is USD 2.85 B for the year ending December 31, 2024, a -2.01% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Chugai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2023 was USD 2.91 B, a 56.10% change year over year.
Chugai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD 1.86 B, a -23.37% change year over year.
Chugai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 2.43 B, a 22.41% change year over year.
Chugai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 1.98 B, a 4.37% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Tokyo Stock Exchange: 4519.T

Chugai Pharmaceutical Co., Ltd.

CEO	Dr. Osamu Okuda
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Nihonbashi Mitsui Tower
Employees	5,026
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.